keyword
MENU ▼
Read by QxMD icon Read
search

Pediatric osteosarcoma

keyword
https://www.readbyqxmd.com/read/28617714/perioperative-chemotherapy-with-and-without-high-dose-methotrexate-in-adult-osteosarcoma
#1
Marcelo Vailati Negrão, Lucila S da Silva Rocha, Daniel da Motta Girardi, Olavo Feher
Treatment of adult osteosarcoma (AOS) includes perioperative chemotherapy and surgery. Standard chemotherapy consists of cisplatin (CP) and doxorubicin (DOX). Although considered the standard of care for pediatric patients, high-dose methotrexate (HDM) remains controversial in adults. We aimed to evaluate the role of HDM in AOS treated with curative intent. This study included patients with AOS who received perioperative chemotherapy with DOX and CP (group 1; N=16) and DOX, CP, and HDM (group 2; N=10). The primary endpoint was grade 3 or superior toxicities...
June 14, 2017: Anti-cancer Drugs
https://www.readbyqxmd.com/read/28616573/yap-and-the-hippo-pathway-in-pediatric-cancer
#2
REVIEW
Atif A Ahmed, Abdalla D Mohamed, Melissa Gener, Weijie Li, Eugenio Taboada
The Hippo pathway is an important signaling pathway that controls cell proliferation and apoptosis. It is evolutionarily conserved in mammals and is stimulated by cell-cell contact, inhibiting cell proliferation in response to increased cell density. During early embryonic development, the Hippo signaling pathway regulates organ development and size, and its functions result in the coordinated balance between proliferation, apoptosis, and differentiation. Its principal effectors, YAP and TAZ, regulate signaling by the embryonic stem cells and determine cell fate and histogenesis...
2017: Molecular & Cellular Oncology
https://www.readbyqxmd.com/read/28611244/fdg-uptake-during-early-adjuvant-chemotherapy-predicts-histologic-response-in-pediatric-and-young-adult-patients-with-osteosarcoma
#3
James C Davis, Najat C Daw, Fariba Navid, Catherine A Billups, Jianrong Wu, Armita Bahrami, Jesse J Jenkins, Scott E Snyder, Wilburn E Reddick, Victor M Santana, M Beth McCarville, Junyu Guo, Barry L Shulkin
The purpose of this study was to determine the relationship of (18)F-fluorodeoxyglucose ((18)F-FDG) uptake in the primary tumor at diagnosis, during therapy, and following therapy with histological response and event-free survival (EFS) in pediatric and young adult patients with osteosarcoma (OS). Methods: Serial (baseline, 5 and 10 weeks after start of therapy) (18)F-FDG positron emission tomography/computed tomography (PET/CT) imaging was obtained in patients with newly diagnosed OS treated uniformly on a therapeutic trial at a single institution...
June 13, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28607872/vascularized-fibula-based-physis-transfer-a-follow-up-study-of-longitudinal-bone-growth-and-complications
#4
Ronnie L Shammas, Yash J Avashia, Alfredo E Farjat, Anthony A Catanzano, L Scott Levin, William C Eward, Brian E Brigman, Detlev Erdmann
BACKGROUND: The vascularized free fibula epiphyseal transfer provides an option for the preservation of limb lengthening after resection of the proximal humerus in pediatric sarcoma patients. The purpose of this study was to provide a long-term follow-up of longitudinal growth patterns and outcomes after free fibula epiphyseal transfer in upper extremity reconstruction. METHODS: A retrospective review of 4 patients who underwent free fibula epiphyseal transfer after oncologic resection of the proximal humerus for osteosarcoma was performed...
May 2017: Plastic and Reconstructive Surgery. Global Open
https://www.readbyqxmd.com/read/28592186/the-role-of-the-mthfr-c677t-polymorphism-in-methotrexate-induced-toxicity-in-pediatric-osteosarcoma-patients
#5
Loes Lambrecht, Charlotte Sleurs, Veerle Labarque, Catharina Dhooge, Annouschka Laenen, Friedl Sinnaeve, Marleen Renard, Anne Uyttebroeck
AIM: Osteosarcoma patients receive high doses of methotrexate (MTX). However, pharmacogenetic information remains limited and has mainly been investigated in leukemia so far. PATIENTS & METHODS: We investigated the link between the MTHFR C677T genotype, toxicity levels (mucositis, MTX plasma level, hematological toxicity and hepatotoxicity) and survival of 48 pediatric osteosarcoma patients. RESULTS: The TT genotype did not show more toxicity compared with the CC/CT genotype...
June 8, 2017: Pharmacogenomics
https://www.readbyqxmd.com/read/28561686/advances-in-the-treatment-of-pediatric-bone-sarcomas
#6
Patrick J Grohar, Katherine A Janeway, Luke D Mase, Joshua D Schiffman
Bone tumors make up a significant portion of noncentral nervous system solid tumor diagnoses in pediatric oncology patients. Ewing sarcoma and osteosarcoma, both with distinct clinical and pathologic features, are the two most commonly encountered bone cancers in pediatrics. Although mutations in the germline have classically been more associated with osteosarcoma, there is recent evidence germline alterations in patients with Ewing sarcoma also play a significant role in pathogenesis. Treatment advances in this patient population have lagged behind that of other pediatric malignancies, particularly targeted interventions directed at the biologic underpinnings of disease...
2017: American Society of Clinical Oncology Educational Book
https://www.readbyqxmd.com/read/28544777/the-prognostic-significance-of-circulating-serum-amyloid-a-and-cxc-chemokine-ligand-4-in-osteosarcoma
#7
Ricardo J Flores, Aaron J Kelly, Yiting Li, Xiang Chen, Colin McGee, Mark Krailo, Donald A Barkauskas, John Hicks, Tsz-Kwong Man
BACKGROUND: Osteosarcoma (OS) is the most common pediatric bone cancer.  Despite advances in treatment regimens, the survival rate remains 60-70%.  There is an urgent need to identify prognostic biomarkers, so that targeted therapies can be developed to improve the outcome. PROCEDURE: Our laboratory has previously identified that circulating serum amyloid A (SAA) and CXC chemokine ligand 4 (CXCL4) are upregulated in patients with OS.  In this study, we tested if they could be used as prognostic biomarkers...
May 24, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/28521633/cd30-expression-in-pediatric-neoplasms-study-of-585-cases
#8
Jinjun Cheng, Haiqing Zhu, John Kim Choi
CD30 is a member of the tumor necrosis factor receptor superfamily, member 8 (TNFRSF8), and its normal expression is restricted to activated T and B cells. In tumor cells, CD30 expression is most commonly associated with lymphoid malignancies (Hodgkin and non-Hodgkin lymphomas) and is a therapeutic target using anti-CD30 antibody. CD30 expression has been reported also in mostly adult non-lymphoid malignancies, raising the possibility of CD30-targeted therapy for additional tumors. In this study, we examined the incidence of CD30 expression in 251 hematopoietic and 334 non-hematopoietic cases of pediatric tumors...
June 2017: Pediatric and Developmental Pathology
https://www.readbyqxmd.com/read/28469335/pediatric-osteosarcoma-an-updated-review
#9
REVIEW
Shachi Jain Taran, Rakesh Taran, Nagraj B Malipatil
Osteosarcoma (OS), the most common type of primary malignant bone tumor, is defined by the presence of malignant mesenchymal cells producing osteoid or immature bone. The peak incidence of the most frequent type of OS, i.e., high-grade central OS, occurs in the second decade of life during the adolescent growth spurt. Most patients suffer from the pain and swelling in the involved region and, usually, seek medical attention. Diagnosis is carried out by conventional radiographs, computed tomography, and magnetic resonance image (MRI)...
January 2017: Indian Journal of Medical and Paediatric Oncology
https://www.readbyqxmd.com/read/28459463/mycn-induces-neuroblastoma-in-primary-neural-crest-cells
#10
R R Olsen, J H Otero, J García-López, K Wallace, D Finkelstein, J E Rehg, Z Yin, Y-D Wang, K W Freeman
Neuroblastoma (NBL) is an embryonal cancer of the sympathetic nervous system (SNS), which causes 15% of pediatric cancer deaths. High-risk NBL is characterized by N-Myc amplification and segmental chromosomal gains and losses. Owing to limited disease models, the etiology of NBL is largely unknown, including both the cell of origin and the majority of oncogenic drivers. We have established a novel system for studying NBL based on the transformation of neural crest cells (NCCs), the progenitor cells of the SNS, isolated from mouse embryonic day 9...
May 1, 2017: Oncogene
https://www.readbyqxmd.com/read/28454389/notch-signaling-is-important-for-epithelial-mesenchymal-transition-induced-by-low-concentrations-of-doxorubicin-in-osteosarcoma-cell-lines
#11
Jian Yang, Weichun Guo, Lu Wang, Ling Yu, Hongjun Mei, Shuo Fang, Anyuan Chen, Yang Liu, Kezhou Xia, Gaiwei Liu
Osteosarcoma is an aggressive pediatric tumor affecting growing bones that typically occurs in adolescents and young adults. Although advances in treatment have been made in recent years, a high proportion of patients relapse due to metastases, which are frequently resistant to chemotherapy and pose a significant threat to long-term survival. Previous studies have demonstrated that the epithelial-mesenchymal transition (EMT) is associated with cancer occurrence and metastasis, and our previous study demonstrated the occurrence of EMT in osteosarcoma...
April 2017: Oncology Letters
https://www.readbyqxmd.com/read/28417853/the-role-of-18-f-fdg-pet-ct-in-pediatric-sarcoma
#12
REVIEW
Douglas J Harrison, Marguerite T Parisi, Barry L Shulkin
Considerable debate remains regarding how best to incorporate (18)F-FDG-PET/CT into clinical practice for pediatric sarcomas. Although there is a clear role for (18)F-FDG-PET/CT in staging pediatric sarcoma, the value of (18)F-FDG-PET/CT in prognostication for pediatric sarcomas remains unclear. In osteosarcoma, Ewing sarcoma, and rhabdomyosarcoma, (18)F-FDG-PET/CT may be most useful in the identification of skeletal metastases, where the literature consistently suggests that it has improved sensitivity and specificity as compared to bone scintigraphy...
May 2017: Seminars in Nuclear Medicine
https://www.readbyqxmd.com/read/28409896/childhood-osteosarcoma-incidence-and-survival-in-argentina-report-from-the-national-pediatric-cancer-registry-roha-network-2000-2013
#13
F Moreno, W Cacciavillano, M Cipolla, M Coirini, P Streitenberger, J López Martí, M Palladino, M Morici, M Onoratelli, G Drago, A Schifino, M Cores, A Rose, J Jotomliansky, M Varel, M García Lombardi
BACKGROUND: Differences in incidence and survival in osteosarcoma reports are considerable worldwide. PURPOSE: This study describes the incidence and survival of patients with osteosarcoma in Argentina with data from the National Pediatric Cancer Registry (ROHA), and the impact of age, gender, stage, regional, and socioeconomic indicators on outcome. METHODS: Pediatric patients with osteosarcoma reported to ROHA from 2000 through 2013 were analyzed, the annual age-standardized incidence rate (ASR) was calculated using the National Vital Statistics, and survival was estimated...
April 14, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/28384657/metronomic-chemotherapy-vs-best-supportive-care-in-progressive-pediatric-solid-malignant-tumors-a-randomized-clinical-trial
#14
Raja Pramanik, Sandeep Agarwala, Yogendra Kumar Gupta, Sanjay Thulkar, Sreenivas Vishnubhatla, Atul Batra, Deepa Dhawan, Sameer Bakhshi
Importance: Although oral metronomic chemotherapy is often used in progressive pediatric solid malignant tumors, a literature review reveals that only small single-arm retrospective or phase 1 and 2 studies have been performed. Skepticism abounds because of the lack of level 1 evidence. Objectives: To compare the effect of metronomic chemotherapy on progression-free survival (PFS) with that of placebo in pediatric patients with primary extracranial, nonhematopoietic solid malignant tumors that progress after at least 2 lines of chemotherapy...
April 6, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28353326/immunotherapeutic-approaches-in-pediatric-osteosarcoma
#15
Hui Cao, Hongwei Zhang, Huaxin Zou
No abstract text is available yet for this article.
March 27, 2017: Minerva Pediatrica
https://www.readbyqxmd.com/read/28326824/osteopontin-its-potential-role-in-cancer-of-children-and-young-adults
#16
Gabrielle Karpinsky, Aleksandra Fatyga, Malgorzata Anna Krawczyk, Madeleine Chamera, Natalia Sande, Dagmara Szmyd, Ewa Izycka-Swieszewska, Ewa Bien
OBJECTIVE: Osteopontin (OPN) is aglyco-phosphoprotein, involved in tissue remodeling, inflammation and boneresorption. In various adult neoplasms OPN was shown to correlate with cancer progression, invasiveness and metastasis. AIM: to define the role of OPN in malignancies of children and young adults. MATERIAL AND METHODS: a structured PubMed and Google Scholar literature analysis based on reports published in English between I'1995 and XII'2015...
March 14, 2017: Biomarkers in Medicine
https://www.readbyqxmd.com/read/28301225/optimal-diagnostic-yield-achieved-with-on-site-pathology-evaluation-of-fine-needle-aspiration-assisted-core-biopsies-for-pediatric-osseous-lesions-a-single-center-experience
#17
Kalyani Patel, Darryl Kinnear, Norma M Quintanilla, John Hicks, Eumenia Castro, Choladda Curry, John Dormans, Daniel J Ashton, J Alberto Hernandez, Hao Wu
CONTEXT: - Image-guided, fine-needle aspiration-assisted core needle biopsy with an on-site evaluation by a pathologist (FNACBP) of osseous lesions is not a common practice in pediatric institutions. OBJECTIVES: - To evaluate the diagnostic adequacy and accuracy of FNACBP for pediatric osseous lesions and to compare the adequacy with procedures that do not use fine-needle aspiration. DESIGN: - Six-year, retrospective review of 144 consecutive children biopsied for osseous lesions with and without fine-needle aspiration assistance...
March 16, 2017: Archives of Pathology & Laboratory Medicine
https://www.readbyqxmd.com/read/28275089/the-microtubule-network-and-cell-death-are-regulated-by-an-mir-34a-stathmin-1-%C3%AE-iii-tubulin-axis
#18
Nancy S Vetter, E A Kolb, Christopher C Mills, Valerie B Sampson
MicroRNA-34a (miR-34a) is a master regulator of signaling networks that maintains normal physiology and disease and is currently in development as a miRNA-based therapy for cancer. Prior studies have reported low miR-34a expression in osteosarcoma; however, the molecular mechanisms underlying miR-34a activity in osteosarcoma are not well-defined. Therefore, this study evaluated the role of miR-34a in regulating signal transduction pathways that influence cell death in osteosarcoma. Levels of miR-34a were attenuated in human osteosarcoma cells and xenografts of the Pediatric Preclinical Testing Consortium (PPTC)...
March 8, 2017: Molecular Cancer Research: MCR
https://www.readbyqxmd.com/read/28272712/the-expression-and-function-of-mirna-106-in-pediatric-osteosarcoma
#19
M Xu, Y-Y Zhang, H-F Wang, G-S Yang
OBJECTIVE: This study is to investigate the expression and biological function of miRNA-106b in osteosarcoma. PATIENTS AND METHODS: Freshly resected osteosarcoma tissues and the corresponding para-carcinoma tissues were collected from 54 patients. Then miR-106b level in the carcinoma tissues was detected by real-time PCR. To test the function of miR-106b, osteosarcoma cell line U2-OS was transfected with miR-106b inhibitor in vitro. Then, the proliferation, cell cycle, invasion and metastasis of U2-OS cells were detected by CCK-8 assay, flow cytometry, and transwell respectively...
February 2017: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/28270069/pathological-and-therapeutic-aspects-of-long-noncoding-rnas-in-osteosarcoma
#20
Kaixiu Wang, Wei Jiang, Chao Cheng, Yusheng Li, Min Tu
BACKGROUND: Osteosarcoma (OS) is a common bone malignant tumor, which is the eighth leading form of pediatric cancer. Despite the modern chemotherapeutic development of OS, a number of patients with OS have a high risk of lung metastasis and local relapse after chemotherapy. OBJECTIVE: This review study focused on the role of long non coding RNAs (lncRNAs) in OS progression, and presented update reports on OS treatment by targeting specific lncRNAs. METHOD: We have acquired information on OS and lncRNAs from scientific databases like google scholar, pubmed and scopus, and reviewed for this study...
February 13, 2017: Anti-cancer Agents in Medicinal Chemistry
keyword
keyword
23005
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"